Pharming Group (PHAR) said Wednesday it received a positive recommendation from the UK's National Institute for Health and Care Excellence for the reimbursement and use of Joenja, or leniolisib, to treat activated phosphoinositide 3-kinase delta syndrome, or APDS, in adults and children at least 12 years of age.
The drug is now available for use in England and is expected to be funded in Wales within the next three months, the company said.
APDS is a rare type of immunodeficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.